Ascendis Pharma Reports Strong Q3 2026 Results Driven by Yorvipath Growth
Ascendis Pharma (ASND) reported significant third-quarter 2026 growth, with product revenue reaching €366 million, an 89% increase year-over-year. This surge was primarily fueled by Yorvipath, which saw revenues climb 103% to €291 million due to robust new patient demand in the US and expansion into over 40 countries. The company also noted a successful commercial launch for Yuviwel, which doubled its revenue from the previous quarter. Financially, the company is moving toward self-sustainability, reporting an operating cash flow of €189 million for the quarter and providing full-year guidance of at least €600 million. While management highlighted long-term revenue targets of up to €10 billion by 2035, they noted a slight delay in the COAST Phase 3 trial due to regulatory feedback requiring a redesigned study structure.
Tickers: $ASND
Topics: Financial Guidance Operating Cash Flow Product Performance Revenue Growth